🟢 TCRX is trading 5.9% up today following positive Phase 1 ALLOHA study data

TCRX is trading at $0.89 (up 5.9%) in after-hours trading as investors digest positive initial data from the ALLOHA Phase 1 study of TSC-101.

• The stock is rebounding from a weak regular session close of $0.84.
• The move follows the June 22, 2026, release of data regarding TSC-101 for the treatment of hematologic malignancies.
• The price action suggests a company-specific sentiment reset, outperforming a mixed broader market.